تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
9.08 US$
−0.14 US$ · -1.52%
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
الإغلاق السابق
9.08 US$
−0.14 US$ · -1.52%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
نطاق اليوم
السعر الحالي 9.08 US$
نطاق 52 أسبوعًا
السعر الحالي 9.08 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
40
مرتفع السعر
المشاعر
62
صعودي
المخاطر
63
مخاطر مرتفعة
الزخم
48
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
نطاق اليوم
السعر الحالي 9.08 US$
نطاق 52 أسبوعًا
السعر الحالي 9.08 US$
الدخل التشغيلي
صافي الدخل
| البند (EUR) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 |
|---|---|---|---|---|
| البحث والتطوير | 48.88 مليون EUR | 39.31 مليون EUR | 26.31 مليون EUR | 19.42 مليون EUR |
| مصاريف البيع والمصاريف العمومية والإدارية | 12.57 مليون EUR | 9.82 مليون EUR | 6 مليون EUR | 4.49 مليون EUR |
| نفقات التشغيل | 59.28 مليون EUR | 48.02 مليون EUR | 31.19 مليون EUR | 22.63 مليون EUR |
| دخل الفوائد | 1.61 مليون EUR | 1.22 مليون EUR | 245 ألف EUR | 71 ألف EUR |
| مصاريف الفوائد | 60 ألف EUR | 67 ألف EUR | 31 ألف EUR | 45 ألف EUR |
| الاستهلاك والإطفاء | 219 ألف EUR | 311 ألف EUR | 99 ألف EUR | 23 ألف EUR |
| الدخل التشغيلي | −59.28 مليون EUR | −48.02 مليون EUR | −31.19 مليون EUR | −22.63 مليون EUR |
| صافي الدخل | −62.55 مليون EUR | −46.27 مليون EUR | −11.39 مليون EUR | −8.14 مليون EUR |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
35.00 US$
ارتفاع محتمل بنسبة 285.46%صناديق متداولة تفصح عن تعرضها لهذا السهم.
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
